i think i have an answer to why and how gnbt is going to spin off a major NASDAQ company when they are really worth only about 40 million and they are asking for an s1 that will give that much to stay alive......and the subsequent question by zoli from Germany that insisted on understanding why give away half of the company just to make this happen.....

generex had ae37 from way after they acquired antigen express....ae37 showed some promise...but with management the way they were, they did not really do anything with it....here comes Merck....they were making about 10 million a quarter on keytruda....but this miracle drug was not effective in treating triple negative affected women (and men)....so they saw the likelihood of ae37 in helping this cause, since some of the scientists involved with the discovery of ae37 had some merck origins (i don't remember whom, maybe rjs can chime on this)...

so when merck comes and offers generex to do a collaborative offer for the ae37.....the valuation of antigen express was raised high, very high....its all potential, nothing else...

Merck can corner the market on breast cancer if they can see good results with ae37.....they can do 15 billion a quarter on keytruda/ae37, if not more...

what does generex get out of this....ae37 works....Ii key peptide technology works....companies from all over the world want to use the tech for making vaccines, for different kinds of cancer (Shenzen) and infectious diseases...